EAM Investors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-13,187
| Closed | -$1.58M | – | 323 |
|
|
2022
Q4 | $1.58M | Sell |
13,187
-166
| -1% | -$19.8K | 0.33% | 136 |
|
|
2022
Q3 | $1.42M | Buy |
13,353
+2,041
| +18% | +$217K | 0.31% | 140 |
|
|
2022
Q2 | $1.1M | Buy |
+11,312
| New | +$1.1M | 0.27% | 177 |
|
|
2018
Q2 | – | Sell |
-41,529
| Closed | -$3.44M | – | 331 |
|
|
2018
Q1 | $3.44M | Buy |
41,529
+3,249
| +8% | +$269K | 0.57% | 44 |
|
|
2017
Q4 | $2.97M | Sell |
38,280
-493
| -1% | -$38.3K | 0.53% | 51 |
|
|
2017
Q3 | $2.38M | Buy |
+38,773
| New | +$2.38M | 0.32% | 140 |
|
|
2016
Q3 | – | Sell |
-55,895
| Closed | -$2.54M | – | 338 |
|
|
2016
Q2 | $2.54M | Sell |
55,895
-25,489
| -31% | -$1.16M | 0.38% | 133 |
|
|
2016
Q1 | $3.22M | Buy |
81,384
+5,171
| +7% | +$205K | 0.5% | 49 |
|
|
2015
Q4 | $4.31M | Buy |
76,213
+18,502
| +32% | +$1.05M | 0.56% | 30 |
|
|
2015
Q3 | $2.3M | Sell |
57,711
-13,421
| -19% | -$534K | 0.36% | 125 |
|
|
2015
Q2 | $3.4M | Buy |
+71,132
| New | +$3.4M | 0.4% | 90 |
|
|
2013
Q3 | – | Sell |
-180,478
| Closed | -$2.42M | – | 350 |
|
|
2013
Q2 | $2.42M | Buy |
+180,478
| New | +$2.42M | 0.52% | 37 |
|